Interesting point Mr. 'Keiturn' and I think it fits the GTC situation fairly well. I--and I think many at the company--expected this technology to get into commercial use well before now.
I have come to believe that decision makers in the 'pharma world' do become highly risk-adverse and seek to minimize
their risks at every turn because the drug development process is so risky. I imagine in the past there were internal discussions where someone at a lower level might extol the potential cost and scalability advantages of transgenic production only to be overruled by an older, higher authority who says "we can't use it until it is a proven and well accepted commercial technology." That is the only explanation I can find as to why some companies have not lined up to use this technology. I think cheaper--by a lot-- and scalability are key advantages which the industry will embrace more eagerly as more transgenically produced products come to market.
In the meantime, making products, like blood related proteins, which don't express well in cell culture seems like a great arena to stay busy in for quite some time.
Off topic but my recall is that the early relational database
efforts were tied to handicapping horse racing. Is that story correct? And, here's to racing goats.
Market Data 
Markets 
AI
